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Abstract
This systematic review presents the latest trends in salivary research and its applications in health and disease. Among the large number of analytes 
present in saliva, many are affected by diverse physiological and pathological conditions. Further, the non-invasive, easy and cost-effective collec-
tion methods prompt an interest in evaluating its diagnostic or prognostic utility. Accumulating data over the past two decades indicates towards 
the possible utility of saliva to monitor overall health, diagnose and treat various oral or systemic disorders and drug monitoring. Advances in saliva 
based systems biology has also contributed towards identification of several biomarkers, development of diverse salivary diagnostic kits and other 
sensitive analytical techniques. However, its utilization should be carefully evaluated in relation to standardization of pre-analytical and analytical 
variables, such as collection and storage methods, analyte circadian variation, sample recovery, prevention of sample contamination and analytical 
procedures. In spite of all these challenges, there is an escalating evolution of knowledge with the use of this biological matrix.
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Introduction
Interest in rapid and less invasive diagnostic tests 
has grown exponentially in the past decade, which 
has led to extensive research on saliva as a biologi-
cal fluid for clinical diagnosis (1). Saliva has some 
advantages compared to blood and urine, two of 
the most used diagnostic fluids in laboratory set-
ting. Saliva collection is easy and non-invasive re-
quiring relatively simple instructions for collection 
and it possesses lower protein content, less com-
plexity and varying composition than serum (2,3). 
Salivary DNA is being routinely used in many clini-
cal laboratories for assessing the genetic suscepti-
bility to various diseases (Table 1). Saliva based 
tests have been successfully used in human immu-
nodeficiency virus (HIV) infection diagnosis (4), 
monitoring renal disease (5), prevention of cardio-
metabolic risk (6), detection and quantification of 
viral nucleic acids (7), forensic medicine investiga-
tions (8), dental studies (9,10) and drug abuse mon-
itoring (8). There are also some studies proposing 
the use of saliva in monitoring physically active in-
dividuals, incremental effort test (2,11,12) and psy-
chological stress (13).
The main functions of saliva include protection 
and integrity maintenance of oral mucosal health 
through lubrication, buffering action, antibacterial 
and antiviral activity, and food digestion (14). Re-
cent proteomic studies have identified and char-
acterized more than 1000 salivary proteins and 
peptides. Most of these are commonly found in 
plasma and some are solely produced and secret-
ed by salivary glands having no correlation with 
blood levels (15). Saliva also contains electrolytes, 
immunoglobulins, metabolites, enzymes, hor-
mones and vitamins (8,16).
In spite of the attractive nature of saliva, its utiliza-
tion should be carefully evaluated in relation to 
standardization of pre-analytical and analytical 
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Table 1. Diagnostic kits based on salivary omics.
variables, such as accurate choice of collection 
methods (stimulated or unstimulated), possibility 
of direct volume quantification, good sample re-
covery and prevention of sample contamination 
with blood and food debris. It is also important to 
verify the possible analyte circadian variation to 
define collection schedules (2,17,18). In addition, 
saliva is a hypotonic fluid compared to plasma, 
some components are found in lower (sodium, 
magnesium, chloride), higher (potassium, calcium, 
bicarbonate, phosphate) and similar (uric acid - 
UA, urea) concentrations (16). Salivary flow rate, 
composition and protein concentration varies 
amongst individuals depending on factors such as 
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age, oral microbial enzymes, sample processing, 
preservation, protease activity etc. The analytical 
methods should be adapted, allowing high sensi-
tivity and reproducibility (19). The aim of this re-
view is to highlight the suitable diagnostic value of 
saliva as a less invasive fluid in health and human 
systemic diseases. This review summarizes a com-
prehensive literature search from various databas-
es. Here we try to portray the impact on saliva due 
to various physiological and pathological aspects 
of human health.
Saliva: secretion, components and 
composition
The whole fluid present in the oral cavity origi-
nates mainly from three salivary glands: parotid, 
submandibular and sublingual. Minor salivary 
glands (bucal, labial, palatal, palatoglossal, lingual) 
located in the oral cavity, gingival crevicular fluid 
with bacteria, epithelial cells, erythrocytes, leuko-
cytes and food debris can contribute in small vol-
ume to the formation of what is designated as 
“oral fluid” or “whole saliva” (14). In this review we 
will adopt the term “saliva” to designate the whole 
oral fluid present in the mouth. Each salivary gland 
secretes a characteristic type of saliva, with differ-
ent ionic and protein characteristics (15). The glan-
dular secretory contribution varies depending on 
its stimulatory status i.e., unstimulated: subman-
dibular ~ 65%, parotid gland ~ 20%, sublingual 
~ 5% and minor glands ~ 10%; artificially stimulat-
ed: parotid gland > 50%, submandibular ~ 35%, 
sublingual and the minor mucous glands ~ 7-8% 
each (14). In resting conditions, an individual se-
cretes approximately 0.1 to 0.3 mL/min, reaching a 
maximum of 7 mL/min when artificially stimulated 
(14). Dehydration, adrenergic stimulation and exer-
cise can decrease the salivary flow rate (20). An in-
crease in unstimulated salivary flow rate, i.e. hy-
persalivation, may occur due to nausea or swal-
lowing very irritating foods, physiological (i.e. cir-
cadian rhythm) or pathological conditions such as 
cerebral palsy, or other severe neurological disor-
ders, Sjögren’s syndrome etc (21).
Several physiological (e.g., mastication, psycholog-
ical stress, physical exercise etc.) (16,20,22) and 
pathological conditions (e.g., bleeding oral cavity, 
cystic fibrosis, multiple sclerosis, epilepsy etc.) may 
alter the production and content of saliva (16). 
Flow and composition of saliva are regulated 
mainly by the activity of the autonomic nervous 
system (ANS). Parasympathetic stimulation results 
in high flow of saliva containing low levels of or-
ganic and inorganic components. Alpha-adrener-
gic stimulation results in low volume of saliva with 
high protein concentration. Due to low mucin con-
centration, this type of saliva presents low viscosi-
ty (16). Conversely, beta-adrenergic stimulation re-
sults in fluid with high protein and mucin content, 
high viscosity and foamy appearance (16,23).
Acinar, duct and myoepithelial cells, irrigated by 
capillary network, constitute the salivary glands. 
Acinar cells’ secretion can be classified as serous 
(produced mainly from the parotid gland), mucous 
(minor glands) or mixed (sublingual and subman-
dibular glands). Table 2 shows the main transport 
mechanisms of salivary components into salivary 
glands (16). Accumulation of ions in the lumen 
generates an osmotic gradient driving water 
through the apical aquaporin-5 channels leading 
to an isotonic plasma-like fluid (24). The acinar cells 
are connected by ducts and the secreted saliva is 
drained to oral cavity through striated and excre-
Transport mechanism Components
Ultrafiltration through 
gap junctions between 
secretory cells
Molecules < 1.9 kDa (ions, water 
and some peptides)
Selective transport via 
passive diffusion
Lipophilic molecules (steroid 
hormones)
Active transport through 
ion channels Ions (Na
+, K+, Cl- and HCO3-)
Water channels 
(Aquaporins) Water
Synthesized and secreted 
in acinar or ductal cells
Organic components 
(lysozyme, lactoferrine, 
peroxidases, cystatins, histatins, 
immunoglobulin A, salivary alpha 
amylase)
Adapted from Aps and Martens (16).
Table 2. Transport mechanism of saliva components into the 
salivary gland.
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tory ducts (14). While saliva passes through sali-
vary ducts, Na+/Cl- are reabsorbed and K+/HCO3- 
are excreted by active transportation through ion 
channels (24). Due to a relative impermeability of 
the ducts to water, the resulting saliva has a hypo-
tonic characteristic in relation to blood. Some sali-
va components are locally produced in salivary 
glands, thus they are not related to plasma con-
centrations. In this case, the salivary flow rate can 
influence their salivary concentration (16).
Proline-rich proteins (PRPs) (acidic PRPs: 20%, basic 
PRPs: 12% and glycosylated PRPs: 5%), mucins = 
20%, amylase = 20% constitute the most abun-
dant proteins in human saliva (25). Immunoglobu-
lin (A and G), cystatins, statherins and all others 
represent 23% of salivary proteins (25). In conjunc-
tion with other organic molecules, such as vita-
mins and lipids, they perform crucial roles in oral 
mucosal immunity (anti-viral, anti-bacterial and 
anti-fungal), protection of teeth and food diges-
tion (Table 3) (26).
Saliva collection methods and storage
Fasting saliva sample is generally preferred as 
some of its components, such as total protein, so-
dium, chloride, are influenced by circadian rhythm 
(2,27-30). However, the time of collection may also 
depend upon the specific constituents analyzed. 
Saliva can be easily collected by passive drool di-
rectly into plastic tubes (unstimulated saliva). Pas-
sive collection is the most recommended method, 
insofar as most analytes may be quantified with-
out any changes in the traditional quantification 
methods. However, the volume of saliva collected 
by this method will be low (23). Neither teeth 
brushing nor food or liquid ingestion (except wa-
ter) are recommended for a few hours prior to 
sample collection, as it may vary saliva secretion 
rate. Food or drink high in sugar content or caf-
feine can stimulate saliva flow rate and lower 
mouth pH levels, both leading to compromised 
antibody–antigen binding and enzyme activity in 
immunoassays (31). Cleaning mouth with water 
(preferably distilled) helps to eliminate residues 
that may hamper analyses (2).
Stimulated saliva may be collected through gusta-
tory stimulation, mastication or citric acid use (8). 
Saliva from individual glands can be collected by 
glandular ducts cannulation or specific collecting 
devices to the glandular ducts emergence area. 
However, these procedures are complex, slow, and 
invasive and would require skilled personnel (32).
There are some commercial devices that facilitate 
saliva collection. Most of them contain a solid 
base, usually a small piece of cotton or polyester 
for saliva absorption and a conical tube for centrif-
ugation and recovery of the collected saliva. 
Among the most common commercial systems 
that use solid bases are: Oral Salimetrics Swab 
(Salimetrics® LLC, USA), Salivette® Cortisol (Sarstedt, 
Newton, NC, USA) and Orapette (Trinity Biotech, 
Dublin, Ireland) (33). However none of these allow 
direct and accurate volume quantification collect-
ed, thus hampering saliva secretion rate estima-
tion (34). Another available collection system is the 
Saliva Collection System (SCS)® (Greiner Bio-One 
GmgH, Kremsmuenster, Austria) (2,19) which uses 
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Adapted from Amerongen et al. (26).
MUC – mucin; PRPs - proline-rich proteins; MUC5B - mucin type 
5B; MUC7 - mucin type 7; SAA - salivary alpha amylase.
Table 3. Main functions of saliva and its components.
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is more elaborate and uses one solution for clean-
ing oral cavity and another to collect saliva. The 
collected saliva is subsequently transferred via 
vacuum system to graduated transport tubes, 
which allow quantifying the total volume of col-
lected solution. This collection system has been 
recently tested using routine laboratory methods. 
It has demonstrated reliable and reproducible re-
sults for measurement of calcium, magnesium (19), 
salivary alpha-amylase (SAA), UA (2), IgA, cortisol, 
drug and medication monitoring (33) and quantifi-
cation of viral RNA (7). However, some analytes 
may suffer interference due to low pH and addi-
tives present in the extraction solution (2,33). 
Choice of collection system should be carefully 
evaluated, taking into account of the analyte to be 
quantified. The use of citric acid as stimulation 
method or cotton / polyester rolls (18) has been 
shown to affect testosterone and cortisol concen-
trations in immunoassays (31,35).
Saliva samples should be refrigerated at 4 °C for 
processing within 3 to 6 hours after collection. 
SAA, UA, total protein and low-molecular-weight 
antioxidants remain stable up to two weeks at 
-20 °C (2). Cortisol concentrations were not affect-
ed when stored at -80 °C for one year or at 5 °C up 
to 3 months (35). Otherwise, concentrations of cor-
tisol were decreased approximately 10% in sam-
ples stored for 30 days at room temperature (35). 
Addition of sodium azide to saliva may inhibit bac-
terial growth and preserve the sample, but may 
cause an interference in immunoassays with 
horseradish peroxidase. Saliva contains several 
bacterial proteases, which can degrade salivary 
proteins affecting some techniques. To avoid this 
pre-analytical issue, it is useful to include protease 
inhibitors and stabilizing substances (aprotinin, le-
upeptin, antipain, pepstatin A, phenyl methyl sul-
fonyl fluoride, EDTA, thimerosal) (23). Saliva sam-
ples should be submitted to preparation steps be-
fore assays. Pre-analytical treatments as used for 
blood or urine samples must also be applied for 
saliva. Saliva samples should be refrigerated and 
transported in a controlled temperature to avoid 
bacterial contamination (33). Standard collection 
procedures have been proposed by the commit-
tee Standard Australia for specimen collection and 
the detection and quantitation of drugs in oral flu-
id (36).
Comparison of saliva and blood 
components
Table 4 shows published reference intervals (RI) for 
some hormones and biochemical parameters in 
saliva compared to plasma (2,5,17,18,27-30,37). 
Some RI found in saliva show a wide range that 
makes clinical interpretation of results difficult. 
When RI is calculated, it includes approximately 
95% of the reference population studied. Besides, 
RI takes into account between subject biological 
variation and analytical variation. One alternative 
to increase the sensitivity/sensibility for interpreta-
tion of results from saliva, is to compare the pa-
tient’s result with his own previous result, which 
acts as the reference change values (2).
Total protein (TP) concentration can be easily 
quantified in saliva with clinical chemistry analyz-
ers without any method modification. However, 
the saliva protein concentration is 10-15 times low-
er compared to plasma (2). SAA, involved in carbo-
hydrate digestion and oral mucosal immunity, cor-
responds to 10-20% of the TP produced by salivary 
glands in the resting condition (25,38). SAA, re-
leased through the activation of ANS, gustatory / 
mechanical stimuli and psychological / physical 
stress, is locally produced with no correlation to its 
activity in blood (22). Lactate dehydrogenase (LD) 
activity in serum increases as a marker of cellular 
necrosis. The RI for LD in saliva is higher than plas-
ma in healthy individuals (Table 4). Some reports 
show increased LD activity in periodontal disease 
compared to healthy individuals (9). Some peptide 
hormones such as insulin are actively transported 
to saliva (39). Cytokines (tumor necrosis factor al-
pha, leptin, ghrelin and epidermal growth factor) 
have been detected in saliva samples (40). Salivary 
human growth hormone (hGh) was correlated to 
serum hGh concentrations at rest (11). Many other 
specific proteins have been identified in saliva us-
ing comprehensive analytical techniques includ-
ing: proteomic analysis, liquid chromatography, 
gel electrophoresis, capillary electrophoresis, Nu-
clear Magnetic Resonance (NMR), mass spectrom-
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Analyte Saliva collection method Saliva Plasma Analysis method/ collection time References
Na+ (mmol/L) Unstimulated Plastic 3.0-29.01 136.0-145.01 FP (28,37)
K+ (mmol/L) Unstimulated Plastic 6.4-36.61 3.5-4.51 ISE (28,37)
Ca2+ (mmol/L) Unstimulated Plastic 0.88-2.51 1.15-1.331 ISE (28,37)
Cl- (mmol/L) Unstimulated Plastic 0-271 98-1071 ISE (28,37)
UA (mmol/L) Stimulated Liquid (SCS®) 0.07-0.321 0.24-0.49 Enzymatic (2,28)
Urea (mmol/L) Unstimulated Polypropylene 1.66-7.5
1 2.16-8.21 Enzymatic (5,28)
Protein (g/L)
Stimulated Liquid (SCS®) 0.17-1.501 60-801 36:30 a.m. Colorimetric (2,28)
Stimulated Liquid (SCS®) 0.18-5.301 34:00 p.m. Colorimetric (2)
TAS (μmol/L) Stimulated Liquid (SCS®) 42-4071 489-7761 FRAP (2)
SAA
Stimulated Liquid (SCS®) 5.0-155.41 not reported 36:30 a.m. Enzymatic (2)
Stimulated Liquid (SCS®) 24.0-368.01 not reported 34:00 p.m. Enzymatic (2)
LD (U/L) Unstimulated Plastic 113-6091 180-3601 Enzymatic (28,37)
Cortisol 
(nmol/L)

















DHEA (nmol/L) Stimulated Cotton (Salivette®) 1.5±0.3




Unstimulated Plastic 18.71±5.012 52.0-280.01 RIA (18,28)
1Reference interval (2.5th and 97.5th percentile); 2mean ± standard deviation; 3specific collection time mentioned due to influence by 
daily circadian rhythm.
FP – flame photometry; ISE – ion selective electrode; UA – uric acid; SCS® – Saliva Collection System (Greiner-Bio One); FRAP – ferric 
reducing ability of plasma method; TAS – total antioxidant status; SAA – salivary alpha amylase; LD –  lactate dehydrogenase;  DHEA 
– dehydroepiandrosterone; RIA –  radioimmunoassay; LC-MS – liquid chromatography-tandem mass spectrometry.
Table 4. Comparison of saliva and blood analytes in different studies.
etry, radioimmunoassay and enzyme-linked im-
munosorbent assay (15,23,41).
Norepinephrine (NE) and epinephrine (E) are de-
tectable in human saliva, but their source is not 
completely related to plasma. The salivary glands 
are sympathetically innervated, so NE in saliva 
could come from salivary sympathetic nerves and 
bloodstream (42). Plasma and saliva catechola-
mines can increase in response to physical (11) or 
psychological stress (22). Some pre-analytical con-
siderations need to be addressed as saliva NE pre-
sent a high inter-individual variation (47%) (42).
Saliva contains different concentrations of electro-
lytes and inorganic buffering compounds which 
originate from serum through active transporta-
tion (37). The electrolyte concentrations in saliva 
may be quantified by flame photometry and ion-
selective electrode (ISE). Potassium concentration 
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in saliva is higher compared to plasma. Conversely, 
the chloride and sodium salivary concentration 
are lower compared to plasma (37). As a result of 
this difference in ion concentrations when analyz-
ing potassium through ISE, the saliva samples 
needs to be diluted (37). Sympathetic stimulation 
can induce changes in salivary flow, reabsorption 
and secretions of electrolytes in the secretory cells, 
modifying the ionic saliva content (20).
Negligible amounts of organic compounds such 
as bilirubin, creatinine, triglycerides and cholester-
ol may be detected in healthy individuals’ saliva 
(2,37). Salivary concentrations of urea and UA are 
similar to plasma and may change as a result of 
metabolic disorders such as kidney disease (5), 
gout (43) or metabolic syndrome (6). Other impor-
tant organic molecules such as ascorbic acid and 
vitamin E constitute the salivary antioxidant de-
fense system (44,45).
Most hormones present in plasma may be meas-
ured in saliva in an unbound/free form. Serum 
proteins that bind to hormones are large and do 
not pass via passive diffusion. Thus, free hormones 
(e.g., cortisol, testosterone, dehydroepiandroster-
one, estriol and progesterone) are present in con-
centrations similar to free plasma fraction (Table 
4). The RI for salivary cortisol can be influenced by 
circadian rhythm, collection method and the ana-
lytical technique (29,30,46).
Saliva in disease management
Saliva can contribute significantly to disease 
screening, risk assessment, intervention evalua-
tion, recurrence prediction and other prognostic 
outcome assessments (8). Progress in salivary diag-
nostics will also depend on establishing clinical 
utility of macromolecules and low molecular 
weight components. In this regard, salivary varia-
tions observed in specific pathological conditions 
have been compared with blood or other body 
fluids (Table 5) (3,47-50). Extensive progress in dif-
ferent disciplines of salivary omics (genomics, 
transcriptomics, proteomics, metabolomics and 
Conditions Comparison carried out Markers / analytes
Correlations 
observed Remarks Reference
Head and neck 
cancer
Saliva – tumor 
tissue Mitochondrial DNA Positive
Increased levels that decreased in 
post-surgical condition (47)
OSCC Saliva-serum p53 antibody Positive
Saliva may offer a specific method for 




tumors Saliva-serum CA 125 Positive
Saliva assay showed better assay 







ErbB-2 protein may have potential use 
in the initial detection
and/or follow-up screening of breast 
cancer in women
(3)
Dengue Saliva-serum Dengue antibody Positive Saliva as an alternative for dengue diagnosis (50)
Sjögren’s 
syndrome Saliva- serum
C-X-C motif chemokine 
13 Positive
CXCL13 may provide an innovative 
approach for managing this disease (3)
HIV Saliva-serum HIV antibody Positive Formulation of a commercially available diagnostic kit OraQuick (63)
EGF - epidermal growth factor; HIV - human immuno deficiency virus.
Table 5. Comparison of saliva with other body fluids / tissue for measurement of various analytes in selected pathological condi-
tions.
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metagenomics) along with development in sup-
porting informatics and statistical tools has led to 
the discovery of disease specific biomarkers (51). 
This part of the review presents various approach-
es used in salivary diagnostics.
Saliva as a fluid for Omics study
Genomic DNA from saliva is found to be highly in-
formative and discriminatory. Progress in salivary 
genomics is favoured by the availability of suffi-
cient quantity of DNA in saliva, its stability when 
stored at high temperatures even for extended 
periods of time and reliable polymerase chain re-
action (PCR) / exome sequencing results (1,47). Its 
application in forensic and clinical investigations is 
augmented by high-throughput technology plat-
forms like genome-wide microarrays (52). The oral 
microbiota (commensal and pathogenic) and rem-
nants of food also contribute to DNA extraction 
from saliva along with desquamated oral mucosal 
cells (source of human genome). Though it can be 
overcome by careful collection techniques, this 
contamination has led to the identification of vari-
ations in the oral microbiome under pathological 
conditions. Latest advancements in kit based sali-
va collection procedures enable isolation of con-
tamination free high quality DNA which can be 
used for several genetic analyses such as clinical 
genetic testing, pharmacogenomic testing, popu-
lation studies etc (53). DNA tests can be catego-
rized into five domains: diagnostic, predictive, pre-
symptomatic, carrier and prenatal (54). Salivary 
DNA based tests are being used in many diagnos-
tic laboratories for mutations and polymorphisms 
associated with disease susceptibility such as can-
cer, periodontal disease, Mendelian diseases etc. 
(Table 1). Transcriptome based studies have identi-
fied majority of investigated salivary RNA to be of 
human genome origin, in spite of the presence of 
a vast oral microbiome (47).
Salivary proteomics is becoming an acceptable 
medium for the detection of various diseases. This 
is mainly due to the advancements in protein ana-
lytical techniques for separation and identification 
(41). Apart from oral diseases (periodontal disease, 
OSCC etc), saliva might also be seen as a potential 
tool for the diagnosis of systemic diseases. As 
there exists an association between chronic perio-
dontal and cardiovascular diseases, an ultra-sensi-
tive microchip assay system for determining sali-
vary C-reactive protein (CRP) has been suggested 
for their diagnosis (55). Differentially abundant 
proteins in preclinical and clinical Type 2 diabetes 
mellitus (DM) patients, relative to healthy controls, 
have been reported. These involve proteins associ-
ated with metabolism, immune response, devel-
opment, cell organization and biogenesis, extra-
cellular matrix, signal transduction and cell motili-
ty. A significant number of these proteins have al-
ready been reported in association with DM in se-
rum or plasma. These proteins may be involved in 
the development of DM associated complications 
or are markers for such complications (56). Anoth-
er study on Type 1 DM induced salivary pepti-
dome alterations revealed high activity of proteas-
es such as matrix metalloproteinase-9 (MMP-9) 
and cathepsin D and presented salivary collagen 
fragments as potential biomarkers to follow up 
DM-related oral damage (57). Salivary proteomic 
profiles in patients with periodontitis and healthy 
subjects, showed distinct change in proteins in 
presence of inflammation, which can lead to the 
improvement of periodontal disease diagnosis 
(58). A study that aimed to explore the presence of 
informative protein biomarkers in the human sali-
va proteome has identified five candidate bio-
markers (M2BP, MRP14, CD59, catalase and profilin) 
for the detection of oral squamous cell carcinoma 
(OSCC) (48). Franzmann et al. (59) used an ELISA 
based CD44 expression assay for screening head 
and neck squamous cell carcinoma. 
Salivary metabolomics has gained extensive at-
tention in the past decade as a disease diagnostic, 
stratification and early detection tool. By assess-
ment of small molecular weight metabolites, the 
salivary metabolome presents a “snapshot” read-
ing of gene function, enzyme kinetic activity, 
changes in metabolic reactions etc (60). These en-
compass a dynamic multi-parametric response of 
living systems to pathophysiological stimuli or ge-
netic information. Hence, acquisition of disorder-
specific salivary metabolic profiles has facilitated 
identification of several biomarker candidate me-
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tabolites. Mass spectrometry (MS) based study on 
OSCC could pinpoint potential metabolites such 
as choline, betaine, pipecolinic acid and L-carni-
tine as markers of established carcinoma (61). Ex-
tended research on OSCC further revealed L-leu-
cine and L-phenylalanine to be independent or 
combinatorial marker/s for disease diagnosis in the 
pre-clinical stage (62). Such studies have used ul-
tra-performance liquid chromatography-tandem 
MS, capillary electrophoresis time-of-flight MS, 
NMR etc as data acquisition tools (60). In spite of 
extensive research in salivary metabolomics for 
specific disease biomarkers in recent past, it is yet 
to become established as a diagnostic medium.
Saliva based research in various disciplines of om-
ics has led to the identification of many disease 
specific biomarkers. Some representative markers 
are presented in Table 6 (26,47,61-67). A few of 
these have reached the commercial stage which is 
compiled in Table 1.
Disorder specific salivary biochemical 
variations
Changes in disease specific biochemical markers, 
which have already been validated in blood, have 
been investigated in saliva. An increase in salivary 
glucose (SGlc) beyond the normal levels in Type 2 
DM has been reported by many investigators (68). 
However there are also contradicting reports 
where decreased SGlc levels in DM as compared to 
the controls was observed (69). Variations in serum 
or saliva sialic acid (SA) levels demonstrate tumor 
burden predictive significance. Increased levels of 
salivary free SA and protein bound SA can distin-
guish premalignant lesions (PML) (70) and OSCC 
(70,71) cases from healthy controls. Higher SA lev-
els were seen in well differentiated OSCC cases 
than in moderately differentiated cases (71). How-
ever, distinction between PML and OSCC could 
not be confirmed by salivary SA variations (70). 
Significantly high TP and total sugar levels in OSCC 
patients in comparison to healthy controls has also 
been reported (71). Significantly different salivary 
chemical composition (variation in K+, urea, and 
Na+ concentration) between Type I DM patients 
and healthy individuals has also been observed 
(72). Estimation of salivary creatinine levels instead 
of serum creatinine is shown to be an alternative 
in diagnosis of chronic kidney disease (73).
Usefulness of saliva as a non-invasive diagnostic 
tool in biobehavioral studies has been considered. 
SAA, the most abundant salivary component, has 
been explored for monitoring sympathetic nerv-
ous system (SNS) activity (74). SNS, a key player in 
fight-and-flight response, holds significance in 
Omic disciplines Marker References
Malignancies
Transcriptomics
Cyclin 1↑, Epidermal growth factor receptor↑, Fibroblast growth factor 19↑, Fibroblast growth 
factor substrate 2↑, Growth regulation by estrogen in breast cancer 1↑, 1-acyl-sn-glycerol-
3-phosphate acyltransferase alpha↓, Beta-2-microglobulin↓, Brain acid-soluble protein 2↓, 
Immediate early response 3↓, IL1B↓, IL-8↑, IL-1β↑, Spermidine/spermine N1-acetyltransferase 
1↑, S100 calcium binding protein P↑
(63-65)
Proteomics
Maspin↑, Stathmin↑, Transketolase↑, Dimethyladenosine transferase↑, v-Ha-ras oncogene↑, 
Type I collagen pro alpha↓, Tumor necrosis factor↓, Alpha-1-B-glycoprotein*, Complement 
factor B proteins*, Beta fibrin↑, S100 calcium binding protein↑, Transferrin↑, Immunoglobulin 
heavy chain constant region γ 2↑, Cofilin-1↑, Transthyretin↓, IL-8↑, IL-1β↑, Mac-2-binding 
protein↑
(65,67)
Metabolomics Choline↑, Betaine↑, Pipecolinic acid↑, L-carnitine↓, L-leucine↓, L-phenylalanine↓ (61,62)
Dental conditions
Proteomics Proline-rich glycoprotein↓, Secretory immunoglobulin A↑, Histatin-5↑, Lactoperoxidase↑, Statherin↓, Truncated cystatin S↓, Cystatins↓, Lysozyme↓ (26,47,66,67)
↑ - increased concentration; ↓ - decreased concentration; *parameters appearing only in the defined  condition; IL – interleukin.
Table 6. Salivary markers identified through omic disciplines.
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psychological / physiological stress management. 
Bosch et al. (74), presented a concise view of the 
conclusions drawn from SAA studies in this regard 
(74). Measurement of SNS mediated SAA activity is 
found to be affected by parasympathetic nervous 
system (PNS) mediated SAA release, a synergistic 
effect of SNS-PNS on protein secretion and PNS in-
fluence on salivary flow rates. However the limita-
tions observed were that these factors are difficult 
to overcome and that these have been overlooked 
in most studies (74). Variations in specific biochem-
ical analytes in saliva under different disease con-
ditions are given in Table 7 (6,9,10,47,50,58,67-
71,73,75,76).
Table 7. Disease specific biochemical analytes in saliva.
Condition Specific salivary markers Reference
Malignancies
SA↑, Long non-coding RNA↑, p53 antibodies*, CA15-3↑, Cellular erythroblastosis 
oncogene B-2↑, Cancer antigen 125↑, Fibroblast growth factor 2↑, Fibroblast growth 
factor receptor 1↑, Prostate specific antigen↑, Cortisol↑, LD↑, Nitrate↑, Adenosine 




Renal condition Cortisol↑, Nitrite*, UA*, Alpha-amylase*, Lactoferrin*, Creatinine↑ (73,75)
Sjogren’s Syndrome Lactoferrin↑, Beta-2-microglobulin↑, Lysozyme C↑, Cystatin C↑, Amylase↓, Carbonic anhydrase↓ (58,75)
Multiple sclerosis IgA↓ (75)
Sarcoidosis Alpha-amylase↓, Kallikrein↓ (75)
Bone turnover markers Deoxypyridinium↑, Osteocalcin↑, Hepatocyte growth factor↑, Interleukin-1-beta↑, Alkaline phosphatase↑ (75)
Cardiovascular diseases
C-reactive protein↑, Myoglobin↑, Creatinine kinase myocardial band↑, Cardiac troponins↑, 
Myeloperoxidase↑, Tumor necrosis factor α↑, Matrix metalloproteinase–9↑, Intercellular 
adhesion molecule-1↑, Soluble CD40 ligand↑, Lysozyme↑
(75)
Dental caries and 
periodontal diseases
Aspartate aminotransferase↑, Alkaline phosphatase↑, UA↓, Albumin↓, Polymeric 
immunoglobulin receptor↓, Actin-related protein 3↓, Carbonic anhydrase VI↓, Interleukin 
1 Receptor antagonist↓, Plastin-2↑, Leukocyte elastase inhibitor↑, Immunoglobulin 
J↑, Immunoglobulin↑, Cystatin S↑, Amylase*, Calprotectin*, Histatins*, Lysozyme↑, 
Lactoferrin↑, Defensins*, Peroxidases*, PRPs*, MUC*, Prostaglandin E(2)*, Albumin↑, LD↑
(9,10,47,75)
Diseases of the adrenal 
cortex Cortisol↑ (75)
Psychological 




Cortisol↑, IgA↓, Lysozyme↓, Chromogranin↑, SAA↑, Lead↑, Cadmium↑ (75)
Infections (bacterial, 
fungal, viral)
Measles virus-specific IgM↑, HIV—HIV-1*, HIV-2—antibodies*, Mycobacterium tuberculosis↑, 
MUC 5B↑, MUC 7↑, Candidiasis immunoglobulins*, Hsp 70*, Calprotectin*, Histatins*, 
MUC*, Basic PRPs*, Peroxidases*, IgM↑, IgG (dengue) ↑
(50,75)
Cystic fibrosis Cathepsin-D↑, LD↑ (75)
Ectodermal dysplasia Inorganic constituents↑, Total protein↑ (75)
Obesity CRP↑, Leptin↑, Insulin↑, Adiponectin↓ (76)
Metabolic Syndrome UA↑ (6)
↑ – increased concentration; ↓ – decreased concentration; *parameters appearing only in the defined condition.
SA – sialic acid; Hsp – heat shock proteins; SAA – salivary alpha amylase; HIV – human immuno deficiency virus, MUC – mucins; PRPs 
– proline-rich proteins; LD – lactate dehydrogenase; UA – uric acid.
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Usefulness of saliva as medium of study in Mende-
lian disease manifestations has also been ex-
plored. Saliva of cystic fibrosis patients exhibited 
high chloride and sodium concentration (77). Chil-
dren with phenylketonuria excreted significantly 
lower quantities of amino acids in saliva compared 
to the controls (78).
Some of this ensuing research in saliva has led to 
the formulation of innovative diagnostic or prog-
nostic methods. Elevated salivary UA levels has led 
to the early detection of renal disease (capillary 
electrophoresis based UA analysis) (79) and dialy-
sis efficacy monitoring (strip test) (80). Determina-
tion of patient specific baseline analyte concentra-
tion will support the use of this strip test in home 
based disease monitoring (80). Yet another assay 
system that measures myeloperoxidase in whole 
saliva, to track periodontal disease progression, 
has been formulated by Sakamoto’s group (81). Af-
ter required validations, these may be used rou-
tinely in clinical laboratories.
Oxidative stress (OS), imbalance in oxidant – anti-
oxidant system, has been implicated in many dis-
eases. This has led to the recent interest in assess-
ing saliva’s potential to detect the body’s OS. Sali-
vary variations in total antioxidant status, its com-
ponents (superoxide dismutase, catalase, UA, glu-
tathione peroxidase, glutathione reductase, glu-
tathione) and other OS markers (malondialdehyde, 
protein thiols, pro-inflammatory cytokine - Vascu-
lar endothelial growth factor and Hepatocyte 
growth factor, advanced glycation products etc) 
have been observed in recurrent aphthous stoma-
titis, DM, gestational DM, parenteral drug addic-
tion, brain tumor and other ailments (69,82,83). As 
OS is a common phenomenon in several disease 
conditions, its biomarkers may not be useful in de-
tecting specific diseases but may play a role in 
their prognosis and management.
Antibodies present in saliva are of diagnostic use 
in a number of infections, including measles, 
mumps, rubella, hepatitis A and B etc (84,85). Ele-
vated salivary levels of antibodies IgG and/or IgM 
against dengue virus could clearly distinguish in-
fected individuals with high sensitivity and speci-
ficity (50). Studies on salivary levels of pneumococ-
cal serotypes in children have shown its use for fu-
ture surveillance studies (86). Recent study by Rua 
et al., (87) has shown that a latent infection of Sim-
ian Foamy Virus, a gorilla strain, can occur in hu-
mans and persist for years in saliva. Elevated levels 
of Capnocytophaga gingivalis, Prevotella melanino-
genica and Streptococcus mitis in OSCC patients 
also showed diagnostic significance (88). Signifi-
cantly increased levels of salivary Streptococcus 
mutans in β-Thalassemia was found to be a predis-
position factor for the prevalence of dental carries 
(89).
Pharmacovigilance potential of saliva 
Considerable investigation has been carried out 
on qualitative and quantitative analysis of drugs 
(including narrow therapeutical index drugs and 
illicit drugs for forensic purpose) and detection of 
commonly abused substances in saliva (Tables 8 
and 9) (8,90-95). A definable relationship between 
concentration of a therapeutic drug in blood (se-
rum) and its concentration in saliva has been con-
Drug 
category





























Cisplatin and Carboplatin (0.13 
and 1.15 mg/L)
(Platinum levels by atomic 
absorption spectrometry)
(8)
Table 8. Saliva based surveillance for specific drugs.
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Table 9. Saliva as a tool in identification of substance abuse.
sidered as a fundamental prerequisite for diagnos-
tic application of saliva. Presence of a drug in sali-
va is influenced by its physicochemical character-
istics (molecular size, lipid solubility, degree of ion-
ization, degree of protein binding etc), its interac-
tion with salivary glands, extravascular metabo-
lism, effect of salivary pH, mechanism of its trans-
fer into saliva, salivary flow rate and drug stability 
in saliva. Non-ionizable drugs or those that are not 
ionized within salivary pH range are considered 
suitable for salivary drug monitoring. Only the un-
bound fraction of the drug in serum is available for 
diffusion into saliva as serum-binding proteins do 
not cross the membrane owing to their size. The 
unbound fraction usually being the pharmacolog-
ically active one, may present an advantage of 
drug monitoring in saliva over serum. Majority of 
studies have observed a significant positive corre-
lation between salivary and serum drug levels 
(8,91). Stimulation of salivary flow and storage du-
ration did not affect this correlation. However, 
pharmacokinetics of drugs in oral fluid is more 
complex than that of blood. Drug detection in this 
specimen will depend on a range of factors includ-
ing dose, frequency of use (i.e. acute versus chronic 
use) and detection limits of analytical assays (96).
Therapeutic drug monitoring (TDM) is performed 
to optimize the management of patients receiving 
drug therapy for the alleviation or prevention of 
disease. It involves the measurement of drug con-
centration in biologic fluids, its correlation with 
the patient’s clinical condition and assists in recog-
nizing the need for changing the dosage or dos-
age intervals. The value of saliva in TDM is emerg-
ing because of its advantages over blood or serum 
particularly its capacity to reflect the free non–
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protein bound pharmacologically active compo-
nent in serum (97). TDM of some anticonvulsants, 
theophylline, carbamazepine, digoxin, topirimate, 
methadone, disopyramide, docetaxel and pacli-
taxel in oral fluid has been studied and supported 
for its routine application (96). The use of saliva has 
even extended to drug testing which comprises 
identification of possible drug-affected drivers, 
workplace testing  particularly following a safety 
incident, to check for possible drug use, testing of 
persons in prisons and other correctional institu-
tions, the monitoring of drug use by drug courts, 
or testing of detainees suspected of a crime who 
may be under the influence of a drug and for sport 
anti-doping test (23). This application involves 
testing for drugs of abuse such as the ampheta-
mines, cocaine and metabolites, opioids such as 
morphine, methadone and heroin, and for canna-
bis. Being basic in nature, drugs such as ampheta-
mines, cocaine and some opioids appear in similar 
or higher concentration in saliva than plasma. Tet-
rahydrocannabinol (THC), the major species pre-
sent from cannabis use, displays similar concentra-
tions in oral fluid compared to blood in the elimi-
nation phase. However, due to local absorption of 
the drug in the oral cavity its concentration in-
creases for a period after use of drug. Depot ef-
fects occur for other drugs such as nicotine (smok-
ing of tobacco), cocaine, amphetamines, or use of 
sub-lingual buprenorphine that allow local ab-
sorption (96). Hydromorphone, phencyclidine, 
pholcodine and sildenafil are some of the forensi-
cally important drugs that have also been meas-
ured in oral fluid (96).
Conclusion
The transfer of scientific knowledge of salivary bi-
omarkers to determine physiological and patho-
logical situations is a challenging process. Most re-
ports on discovered candidate biomarkers have 
been only preliminary and require extensive vali-
dation in large patient or subject cohorts before 
they can be translated into real world diagnostic 
and screening applications. Saliva being the first in 
line to come in contact with any ingested sub-
stance its composition may be influenced by med-
ication, oral lesions, intracellular diffusion, proteo-
lytic enzymes derived from host, oral micro-or-
ganisms, exercise and circadian patterns. Thus, 
standardized collection methods are needed. As 
biomarkers are generally at very low concentra-
tions in saliva, there is a demand for development 
of specific and sensitive analytical methods and a 
need to concentrate on a multi-marker approach. 
Certain barriers to be tackled before its routine 
commercial recognition are economics of saliva 
based kits, its approval by health and human ser-
vice authority and acceptance by clinicians. De-
spite these limitations, interest in saliva as a diag-
nostic or screening medium has advanced expo-
nentially in the last 10 years.
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